Details

Autor(en) / Beteiligte

• Hu, P
• Shang, J
• Zhang, W H
• Gong, G Z
• Li, Y G
• Chen, X Y
• Jiang, J N
• Xie, Q
• Dou, X G
• Sun, Y T
• Li, Y F
• Liu, Y X
• Liu, G Z
• Ma, D W
• Chi, X L
• Tang, H
• Li, X O
• Xie, Y
• Chen, X P
• Jiang, J J
• Zha, P
• Hou, J L
• Gao, Z L
• Fan, H M
• Ding, J G
• Zhang, D Z
• Ren, H

Titel

HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study

Ist Teil von

• Zhonghua gan zang bing za zhi, 2018-10, Vol.26 (10), p.756

Ort / Verlag

China

Erscheinungsjahr

2018

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous NA. Hepatitis B e antigen (HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA < 200 IU/mL with previous adefovir, lamivudine or entecavir treatment were randomized 1:1 to receive Peg-IFN alfa-2a for 48 ( = 153) or 96 weeks ( = 150). The primary endpoint of this study was HBsAg loss at end of treatment. The ClinicalTrials.gov identifier is NCT01464281. At the end of 48 and 96 weeks' treatment, 14.4% (22/153) and 20.7% (31/150) of patients, respectively, who switched from NA to Peg-IFN alfa-2a cleared HBsAg. Rates were similar irrespective of prior NA or baseline HBeAg seroconversion. Among those who cleared HBsAg by the end of 48 and 96 weeks' treatme